参考文献/References:
[1]周辉,卢淮武,彭永排,等.2015年NCCN宫颈癌临床实践指南解读[J].中国实用妇科与产科杂志,2015,31(3):185-191. [2]Boutas I,Sofoudis C,Kalampokas E,et al.Fertility preservation in women with early stage cervical cancer.Revie of the literature[J].Eur J Gynaec Oncol,2014,35(4):373-377. [3]雷傲利,李勇平.宫颈癌根治术后体外盆腔放疗联合阴道腔内放疗临床研究[J].医疗装备,2016,29(10): 34,35. [4]Luo J,Zhu W,Tang Y.Artemisinin derivative artesunate induces radiosensitivity in cervical cancer cells in vitro in vivo[J].Radiat Oncol,2014,39(5):84-85. [5]方梓羽,段慧,陈春林,等.中国大陆部分医院宫颈癌术前新辅助化疗情况大数据调查和分析[J].中国实用妇科与产科杂志,2018,34(1):100-105. [6]卢淮武,陈浩,刘昀昀,等.宫颈腺癌Ⅰb期患者卵巢转移情况的临床分析[J].中华医学杂志,2016,96(3):203-206. [7]姜文轩,王璐,刘萍,等.中国大陆部分地区局部晚期宫颈癌术前静脉化疗和术前动脉化疗对比研究[J].中国实用妇科与产科杂志,2018,34(11):1253-1257. [8]王彬,赵洪亮.同步化疗联合辅助化疗治疗中晚期宫颈癌疗效观察[J].中国实用医刊,2015,40(13):29-31. [9]刘慧强.我国宫颈癌流行病学特征和高危因素分析[J].中国妇幼保健,2016(6):1258-1260. [10]何咏梅.贝伐单抗、紫杉醇和顺铂联合应用治疗晚期宫颈癌的临床效果[J].中国卫生标准管理,2016,7(15):108-109. [11]Jin YM,Xu TM,Zhao YH.In vitro and in vivo anti-cancer activity of formononetin on human cervical cancer cell line HeLa[J].Tumor Biol,2014,35(3):2279-2284. [12]武雅琴,陆谔梅.同步放化疗和单纯放疗治疗局部晚期宫颈癌的临床观察[J].中外医学研究,2015,13(24):34-35 [13]张秀珍,范江河,尤鑫,等.动、静脉化疗对未控或复发性宫颈癌的疗效观察[J].四川医学,2016,37(5):477-480. [14]李雪梅,王纯雁.贝伐单抗联合紫杉醇和奈达铂治疗晚期及复发宫颈癌的疗效观察[J].现代药物与临床,2016,10(2):203-206. [15]陈明晓.顺铂同步放化疗与单纯放疗治疗中晚期宫颈癌临床对照研究[J].当代医学,2016,22(2):118-119. [16]陆国权,周晓红,陈红,等.多西他赛联合顺铂化疗同步放疗治疗中晚期宫颈癌效果观察[J].山东医药,2016,56(38):83-84. [17]陈菁,徐洋,王俊杰,等.西黄丸对三维适形放疗联合腔内后装放疗治疗中晚期宫颈癌近期疗效影响[J].现代中西医结合杂志,2016,25(26):2916-2918. [18]唐滟,袁亚维,彭培清,等.调强放疗同步两种方案化疗治疗宫颈癌近期疗效及不良反应对比分析[J].现代肿瘤医学,2016,24(22):3611-3615. [19]Pfaendler KS,Wenzel L,Mechanic MB,et al.Cervical cancer survivorship:Long-term quality of life and social support[J].Clin Ther,2015,37(1):39-48. [20]梁朝晖.多西他赛联合顺铂化疗同步放疗治疗中晚期宫颈癌的临床效果[J].中国实用医刊,2019,46(5):34-36. [21]刘海霞.紫杉醇联合卡铂化疗同步放疗治疗中晚期宫颈癌近期疗效观察[J].山东医药,2017,57(6):83-84. [22]Ditto A,Martinelli F,Bogani G,et al.Fertility-Sparing Surgery in Early-Stage Cervical Cancer Patients:oncologic and reproductive outcomes[J].Int J Gynecol Cancer,2015,25(3):493-497. [23]Vici P,Mariani L,Pizzuti L,et al.Emerging Biological Treatments for Uterine Cervical Carcinoma[J].J Cancer,2014,5(2):86-97. [24]童武松,王松林,潘金华.顺铂联合紫杉醇同步放化疗对中晚期宫颈癌患者免疫功能及血清CY-FRA21-1、SCC-Ag的影响[J].海南医学院学报,2016,22(23):2866-2868. [25]黄卫平.术后辅助化疗对有早期高危因素宫颈癌患者预后的影响[J].河北医药,2015,35(17):2630-2631. [26]Trifiletti DM,Swisher-McClure S,Showalter TN,et al.Utilization of postoperative chemoradiotherapy among women in the United States with high- risk cervical cancer[J].Am J Clin Oncol,2018,41(5):452-457. [27]Kim HS,Kim K,Ryoo SB,et al.Conventional versus nerve-sparing radical surgery for cervical cancer:a meta-analysis[J].J Gynecol Oncol,2015,26(2):100-110.
相似文献/References:
[1]廖加群,曹 雪,陈燕平,等.宫颈癌盆腔淋巴结转移分布及危险因素分析[J].医学信息,2018,31(03):25.[doi:10.3969/j.issn.1006-1959.2018.03.008]
LIAO Jia-qun,CAO Xue,CHEN Yan-ping,et al.Distribution and Risk Factors of Pelvic Lymph Node Metastasis in Cervical Cancer[J].Medical Information,2018,31(11):25.[doi:10.3969/j.issn.1006-1959.2018.03.008]
[2]宁尚波,杨东红,付 爽.选择性动脉灌注化疗在口腔癌治疗中的进展[J].医学信息,2018,31(03):28.[doi:10.3969/j.issn.1006-1959.2018.03.009]
NING Shang-bo,YANG Dong-hong,FU Shuang.Progress of Selective Arterial infusion Chemotherapy in the Treatment of Oral Cancer[J].Medical Information,2018,31(11):28.[doi:10.3969/j.issn.1006-1959.2018.03.009]
[3]李杰萍,姜翠红,管树荣,等.化疗患者PICC置管前后心理体验的质性研究[J].医学信息,2018,31(05):164.[doi:10.3969/j.issn.1006-1959.2018.05.060]
I Jie-ping,JIANG Cui-hong,GUAN Shu-rong,et al.Qualitative Study of Psychological Experience before and after PICC Catheterization in Patients undergoing Chemotherapy[J].Medical Information,2018,31(11):164.[doi:10.3969/j.issn.1006-1959.2018.05.060]
[4]徐 洁.宫颈癌筛查及预防的研究进展[J].医学信息,2018,31(09):70.[doi:10.3969/j.issn.1006-1959.2018.09.022]
XU Jie.Advances in Screening and Prevention of Cervical Cancer[J].Medical Information,2018,31(11):70.[doi:10.3969/j.issn.1006-1959.2018.09.022]
[5]黄 花,徐冬冬,章丽霞.TGF-β1在宫颈癌中的研究进展[J].医学信息,2018,31(12):31.[doi:10.3969/j.issn.1006-1959.2018.12.011]
HUANG Hua,XU Dong-dong,ZHANG Li-xia.Research Progress of TGF-β1 in Cervical Cancer[J].Medical Information,2018,31(11):31.[doi:10.3969/j.issn.1006-1959.2018.12.011]
[6]夏易曼娜,李虎成.腹腔镜下宫颈癌根治术与传统开腹手术的对比研究[J].医学信息,2018,31(12):115.[doi:10.3969/j.issn.1006-1959.2018.12.036]
XIA Yi-manna,LI Hu-cheng.Comparative Study of Laparoscopic Radical Resection of Cervical Cancer and Traditional Open Surgery[J].Medical Information,2018,31(11):115.[doi:10.3969/j.issn.1006-1959.2018.12.036]
[7]杨 军,王翠平,李 龙,等.义安区体检HPV-DNA筛查结果分析[J].医学信息,2018,31(14):136.[doi:10.3969/j.issn.1006-1959.2018.14.041]
YANG Jun,WANG Cui-ping,LI Long,et al.Analysis of the Results of HPV-DNA Screening in the Medical Examination of Yian District[J].Medical Information,2018,31(11):136.[doi:10.3969/j.issn.1006-1959.2018.14.041]
[8]王双英,张 娜,刘 芳.具有高危复发因素的早期宫颈癌术后辅助治疗进展[J].医学信息,2018,31(15):33.[doi:10.3969/j.issn.1006-1959.2018.15.012]
WANG Shuang-ying,ZHANG Na,LIU Fang.Advances in Postoperative Adjuvant Therapy for Early Cervical Cancer with High Risk of Recurrence[J].Medical Information,2018,31(11):33.[doi:10.3969/j.issn.1006-1959.2018.15.012]
[9]聂小凤,翟慧慧,冷天艳,等.宫颈脱落细胞miR34a检测在HR-HPV阳性患者
分流中的作用分析[J].医学信息,2018,31(16):43.[doi:10.3969/j.issn.1006-1959.2018.16.012]
NIE Xiao-feng,ZHAI Hui-hui,LENG Tian-yan,et al.Analysis of the Role of MiR34a in Cervical Exfoliated Cells in Shunt of HR-HPV Positive Patients[J].Medical Information,2018,31(11):43.[doi:10.3969/j.issn.1006-1959.2018.16.012]
[10]吴晓玲,周桂华.miR-187在宫颈癌中的表达与临床病理关系的研究[J].医学信息,2018,31(16):69.[doi:10.3969/j.issn.1006-1959.2018.16.019]
WU Xiao-ling,ZHOU Gui-hua.Expression of miR-187 in Cervical Cancer and Its Relationship with Clinicopathological Features[J].Medical Information,2018,31(11):69.[doi:10.3969/j.issn.1006-1959.2018.16.019]
[11]葛文军,宋继荣.紫杉醇联合洛铂在局部晚期宫颈癌患者术前新辅助化疗中的应用[J].医学信息,2020,33(13):106.[doi:10.3969/j.issn.1006-1959.2020.13.029]
GE Wen-jun,SONG Ji-rong.Paclitaxel Combined with Lobaplatin in Neoadjuvant Chemotherapy for Patients with Locally Advanced Cervical Cancer[J].Medical Information,2020,33(11):106.[doi:10.3969/j.issn.1006-1959.2020.13.029]